Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
347.83B
Market cap347.83B
Price-Earnings ratio
116.11
Price-Earnings ratio116.11
Dividend yield
2.34%
Dividend yield2.34%
Average volume
10.81M
Average volume10.81M
High today
$146.61
High today$146.61
Low today
$140.30
Low today$140.30
Open price
$145.55
Open price$145.55
Volume
5.25M
Volume5.25M
52 Week high
$156.92
52 Week high$156.92
52 Week low
$82.01
52 Week low$82.01

Stock Snapshot

With a market cap of 347.83B, Merck(MRK) trades at $140.99. The stock has a price-to-earnings ratio of 116.11 and currently yields dividends of 2.34%.

On 2026-10-26, Merck(MRK) stock traded between a low of $140.30 and a high of $146.61. Shares are currently priced at $140.99, which is +0.5% above the low and -3.8% below the high.

Merck(MRK) shares are trading with a volume of 5.25M, against a daily average of 10.81M.

During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.

During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.

MRK News

Reuters 2h
Merck's therapy extends survival in hard-to-treat uterine cancer patients - Reuters

...

Merck's therapy extends survival in hard-to-treat uterine cancer patients - Reuters
Zacks 5h
Countdown to Merck Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

The upcoming report from Merck (MRK Quick QuoteMRK - Free Report) is expected to reveal quarterly earnings of $2.12 per share, indicating a decline of 17...

Countdown to Merck Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Simply Wall St 1d
What Merck's Melanoma Vaccine Trial Win Means For Shareholders

Merck and Moderna reported detailed Phase 3 INTerpath-001 results showing that personalized mRNA therapy intismeran plus Keytruda cut recurrence or death risk b...

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More MRK News

Simply Wall St 2d
Merck Stock May Be 38% Undervalued Following Melanoma Vaccine Results

has delivered a powerful multi year share price run and a packed oncology news flow, which naturally raises a simple question for you as an investor. Is the cur...

24/7 Wall St. 3d
AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

Investing AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s? When a drugmaker's top product loses patent protection, the dividend usually...

AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?
MarketWatch 3d
The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

Moderna and Merck proved their custom cancer vaccine cut the risk of melanoma returning for longer than the cancer drug Keytruda, but it may take several years...

The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
Zacks 3d
MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress

Moderna (MRNA Quick QuoteMRNA - Free Report) , along with partner Merck (MRK Quick QuoteMRK - Free Report) , reported detailed positive results from t...

MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress
24/7 Wall St. 3d
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

Investing Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip Full late-stage results for the personalized melanoma vac...

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Simply Wall St 3d
Merck Releases Phase 3 Melanoma Vaccine Data, Is It Fully Priced?

Merck (MRK) is back in the spotlight after detailed Phase 3 INTerpath-001 data showed its personalized melanoma vaccine intismeran, combined with Keytruda, cut...

CNBC 4d
Moderna shares plunge after leak of cancer vaccine data despite positive results

Moderna shares dropped as much as 25% on Thursday following the leak of partial data on its closely watched cancer vaccine developed with Merck . Shares of bot...

Moderna shares plunge after leak of cancer vaccine data despite positive results

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.